Clinical Trial Update: Deucravacitinib (BMS-986165) for Pityriasis Rubra Pilaris [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for Deucravacitinib in pityriasis rubra pilaris. The study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pityriasis Rubra Pilaris

Drugs mentioned

• Deucravacitinib (deucravacitinib)

Snippet

Sponsor: Mayo Clinic | Conditions: Pityriasis Rubra Pilaris | Phase 2 | Status: RECRUITING